Opinion
Video
ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC
Author(s):
Key Takeaways
- Osimertinib significantly improved progression-free survival in unresectable stage III EGFR-mutated NSCLC post-definitive CRT, as shown in the phase 3 LAURA trial.
- The trial results suggest osimertinib may become a new standard of care for patients with EGFR-mutated NSCLC, enhancing treatment strategies.
Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.
Video content above is prompted by the following questions:
- Discuss the data that was presented at the 2024 ASCO Annual Meeting on the progression-free survival from the phase 3 trial LAURA of osimertinib in patients with unresectable stage III EGFR-mutated NSCLC without progression after definitive CRT.
- What are your key takeaways from this study and how will it impact the current standard of care for EGFR-mutated NSCLC?
Related Videos
Related Content
January 1st 2025
December 26th 2024
December 23rd 2024
Precision Oncology in NSCLC: Overcoming Patient Selection Barriers
